Brivaracetam
- (2S ) -2 - [ (4R )-2- oxo-4- propylpyrrolidin -1-yl ] butanamide
- UCB 34714
Anticonvulsant
Ligand on the synaptic vesicle protein 2A
Template: Infobox chemical / molecular formula search available
The drug is an orally Brivaracetam appliqued anticonvulsant. Brivaracetam was developed by the Belgian company UCB and is marketed under the trade name Rikelta.
Pharmacology
Mechanism of Action
Brivaracetam is a ligand synaptic vesicle protein 2A on ( SV2A ). Additionally, it inhibits the voltage -dependent sodium channels in the nervous system. Brivaracetam chemically derived from levetiracetam, wherein it has a 10 times greater anticonvulsant activity due to its higher affinity for the receptor SV2A.
Properties
Brivaracetam is absorbed almost completely orally and excreted by the kidney, the renal clearance is 0.06 mL / min / kg. Brivaracetam has a volume of distribution of 0.6 L / kg and is degraded both by CYP -dependent, and CYP - independent pathways. It is slightly toxic to the liver and studies on the carcinogenic effects in vitro ( Ames test) were negative. However, high doses Brivaracetam lead in combination with Carbamazepinen to faster degradation of these. Its plasma half-life of 8 hours and the plasma protein binding is less than 20 %.